Genentech

A Member of the Roche Group

Pharmaceutical Industry Fellowship Program 2024 - 2025

in partnership with

RUTGERS

Institute for Pharmaceutical Industry Fellowships

Doing now what patients need next

Genentech
A Member of the Roche Group

DEAR PROSPECTIVE FELLOW

On behalf of the Roche Group and the Ernest Mario School of Pharmacy at Rutgers University, we thank you for your interest in a Fellowship at Genentech, a member of the Roche Group. A global pioneer in healthcare since 1896, Roche is a world leader in biotechnology and in vitro diagnostics, creating and delivering innovative medicines and diagnostic tests for patients worldwide. We are passionate and rigorous about our science. With a history of more than 35 years in the Fellowship, Roche has also played a major role in fostering the professional growth of pharmacists in pharmaceutical research, development, and commercialization. We offer motivated PharmD graduates, who share our purpose to improve the lives of patients, exciting opportunities to develop their skills and pursue their interests at Genentech's US Headquarters for Roche Pharmaceutical Operations in South San Francisco, California, where the biotechnology industry began and continues to thrive.

We aim to cultivate one of the best educational environments for PharmD graduates through our commitment to quality and excellence. Fellows have the opportunity to develop or enhance their knowledge and skills while experiencing a corporate culture that encourages diversity of thought, style, skill, and perspective as well as a dynamic environment of international colleagues. While the Fellowship is structured, it is still flexible enough to allow participants to engage in a wide array of unique opportunities and obtain a solid experience in the healthcare industry. We look forward to meeting you and discussing how this program can serve as your pathway to an exciting career in helping to improve patients' lives.

Patrick Schleck, PharmD, MBA

Vice President, Head of Oncology Partnering
Pharma Partnering
Genentech RPIF Program Director

TABLE OF CONTENTS

Genentech
A Member of the Roche Group

ABOUT ROCHE & GENENTECH

MEET THE LEADERSHIP TEAM

PATRICK SCHLECK, PharmD, MBA
Vice President, Head of Oncology Partnering
Pharma Partnering
Genentech RPIF Program Director



JAN BHAGWAKAR, PharmD
Medical Science Liaison Field Director
(Central/Southeast) - Lung/GU/Derm
Oncology

MICHAEL STAMATIS, PharmD
Regulatory Senior Program Director,
Product Development Regulatory

TODD OKAMOTO, PharmD
Medical Science Liaison Field Director
(West), Lung/GU/Derm Oncology

WHO WE ARE

We have always worked to drive scientific discovery and redefine what is possible to improve patients' lives. We are working on understanding how diseases differ down to the molecular level to develop new tests and medicines that prevent, diagnose, and treat diseases that matter and bring them to the patients who need them. With our combined strengths in diagnostics and pharmaceuticals, our personalized healthcare strategy aims to fit the right treatment to the right patient.

As the world's largest biotech company, we develop breakthrough medicines, improving the standard-of-care across oncology, immunology, infectious diseases, ophthalmology and neuroscience. This track record allows us to build lasting and meaningful partnerships across the world with research academia and public healthcare institutions. The founding families continue to hold the majority stake in the company. This stability allows for a tradition of sustainable thinking, so we can learn from setbacks and focus on lasting value for patients and society. We remain dedicated to the highest standards of quality, safety, and integrity. Our legacy is based on respect for the individual, the communities and the world we live in.

OUR PURPOSE

We believe it is urgent to deliver medical solutions right now – even as we develop innovations for the future. We are passionate about transforming patients' lives. We are courageous in both decision and action. And we believe that good business means a better world. That is why we come to work each day.

We commit ourselves to scientific rigor, unassailable ethics, and access to medical innovations for all. We work to foster belonging for our people, and advance inclusive research and health equity for all patients. We do this today to build a better tomorrow. We are proud of who we are, what we do, and how we do it. We are many, working as one across functions, across companies, and across the world.

Innovation: It's in our DNA

ABOUT ROCHE & GENENTECH

OUR HISTORY

Founded in 1976, Genentech is a leading biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.

In 2009, Genentech became a member of the Roche Group—now the largest biotechnology company in the world. Genentech's South San Francisco campus serves as the headquarters for Roche pharmaceutical operations in the United States.

Today, as a member of the Roche Group, we are the global leader in personalized healthcare, leveraging our combined strengths across pharmaceuticals, diagnostics and data insights to fundamentally change the way diseases are treated.

32	MEDICINES IN THE WORLD HEALTH ORGANIZATION MODEL LIST FOR ESSENTIAL MEDICINES
39	FDA BREAKTHROUGH THERAPY DESIGNATIONS
40+	FDA-APPROVED MEDICINES FOR SERIOUS & LIFE-THREATENING DISEASES
80+	INVESTIGATIONAL DRUGS IN DEVELOPMENT

$14.7 B
IN RESEARCH & DEVELOPMENT

700+
CLINICAL TRIALS IN THE U.S.

1150+
CLINICAL TRIALS WORLDWIDE

7 AREAS OF FOCUS

ONCOLOGY, IMMUNOLOGY, INFECTIOUS DISEASES, METABOLISM, OPHTHALMOLOGY, NEUROSCIENCE, AND OTHER

GENENTECH AT A GLANCE



Genentech
A Member of the Roche Group

CULTIVATING A GREAT WORKPLACE

FORTUNE 100 BEST COMPANIES TO WORK FOR	24 Years on the List	BEST Workplaces for Commuters 2021	6 Years on the List
Science 2018 TOP EMPLOYER	21 Years on the List	Forbes 2021 THE BEST EMPLOYERS FOR DIVERSITY	6 Years on the List
TOP CORPORATE PHILANTHROPISTS 2020	17 Years on the List	2018 COMPANIES THAT CARE	5 Years on the List
BEST PLACES TO WORK 2018 for LGBTQ Equality 100% CORPORATE EQUALITY INDEX	16 Years on the List	FORTUNE BEST WORKPLACES IN BIOPHARMA 2020	6 Years on the List
COMPUTERWORLD 100 2018 BEST PLACES TO WORK in IT	14 Years on the List	BEST WORKPLACES FOR INNOVATORS FAST COMPANY	3 Years on the List

ROCHE GROUP

Pharma

Roche | Genentech A Member of the Roche Group | Spark Therapeutics | Chugai

Diagnostics

Roche

- Centralized and Point of Care Solutions
- Molecular Diagnostics
- Tissue Diagnostics
- Sequencing
- Diagnostics Information Solutions
- Diabetes Care

Insights

flatiron | FOUNDATION MEDICINE

Genentech
A Member of the Roche Group

FELLOWSHIP COMPONENTS

At Genentech, fellows are valuable assets within their chosen functional area. Rooted in our commitment to pursuing groundbreaking science and addressing unmet needs, this robust program builds the best leaders in the pharmaceutical industry. It has established a lasting tradition of furthering the development of fellows, allowing them to fine tune skills, fully integrate into a corporate setting, network, and make lasting contributions on patients.

MENTORSHIP PROGRAM

The mentorship program pairs fellows with experienced mentors currently on their team either within Genentech or Roche. This provides the fellow with additional support in their day-to-day activities outside of their co-fellows & preceptors.

The mentorship program aims to give fellows continued career guidance and professional development through the collaborative efforts of Genentech and Roche.

NETWORKING OPPORTUNITIES

- **Pharmacists Network**
  Network with other PharmDs at Genentech
- **Genentech Rotational Network**
  Network with professionals completing rotational programs at Genentech
- **Training & Development Partnership**
  Provides training across functional roles and therapeutic areas for commercial colleagues and provides soft skills & behavioral trainings for all Genentech employees

Genentech
A Member of the Roche Group

ROTATION OPPORTUNITY

At Genentech, we prioritize the development of each fellow. Our fellowships are structured to maximize exposure to various roles within industry, specifically within the fellow's chosen functional area. Certain fellowships offer a rotational opportunity during the fellow's second year in order to gain hands-on experience in an additional functional area of interest.

FELLOWSHIP ALUMNI NETWORK

- Roche was one of the first companies to partner with RPIF
- There are 50+ RPIF Alumni currently employed at Roche/Genentech
- Many preceptors & Fellowship Leadership Team members are RPIF alumni & are actively engaged

PROFESSIONAL CURRICULUM

- Professional Development series at the Ernest Mario School of Pharmacy (EMSOP)
- Optional Teaching and Learning Certificate Program at EMSOP
- Genentech skill development courses customized to Fellow interest each year

SOCIAL

LinkedIn, Facebook, Instagram: *@RutgersFellow*
Rutgers Website: pharmafellows.rutgers.edu

Genentech
A Member of the Roche Group

OVERVIEW OF FELLOWSHIP POSITIONS

Recruiting for 2024 – 2026
(all positions are two years in length)

2 Fellows	Global Clinical Operations	**1 Fellow**	USMA / Medical Communications
2 Fellows	Clinical Science Late Stage Development	**2 Fellows**	USMA / Medical Science Liaisons
1 Fellow	Product Development Clinical Safety	***Not recruiting***	USMA / Clinical Operations / Study Leadership
1 Fellow	Regulatory Affairs	***Not recruiting***	Pharma Partnering



Genentech
A Member of the Roche Group

GLOBAL CLINICAL OPERATIONS

OVERVIEW

At Roche/Genentech, we have a bold Pharma Vision to achieve 3-5 times more patient benefit at 50% less cost to society. With this vision top of mind, Pharma Product Development (PD) Global Clinical Operations' (PDG) mission is to become an industry leader and disruptor in re-inventing how we organize ourselves and work. We seek to create new ways of working, always with the patient at the center of everything we do. Our shared purpose is to innovate clinical trial delivery to transform Roche's patient, caregiver, and site experience to bring better trials to more patients.

Working cross-functionally, fellows will contribute to the delivery of the PD portfolio of clinical studies and programs across Disease Areas by providing operational and/or strategic input. Additionally, you may help architect the Disease Area Operational Strategy to enable trial execution and deliver a better future for patients by contributing to Roche's Personalized Healthcare mission of ensuring the right treatment for the right patient at the right time.

Within Clinical Operations, Genentech offers global fellowship positions in the following areas (with potential to contribute to multiple disease areas):

- Oncology, Immunology, Infectious Diseases, Ophthalmology, and Neuroscience

ACTIVITIES

Fellow responsibilities may include:

- Providing direction and leadership to the operations communities, while collaborating closely cross-functionally
- Serving as a partner to local internal and external stakeholders globally and help support local business needs
- Providing operational input to the development of study deliverables, such as feasibility questionnaires and patient recruitment and retention strategies
- Organizing investigator meetings, monitor trainings, and Contract Research Organization (CRO) kick-off meetings
- Developing and managing operational plans related to site monitoring, risk mitigation, trial budgets, site selection, study timelines, quality and clinical supplies
- Establishing and driving timelines for study milestones and ensuring accurate tracking and reporting of study metrics
- Promoting and supporting quality and compliance
- Engaging in department and disease area-wide strategic activities to further improve study delivery

PRECEPTORS

Jenee Pan, PharmD
Clinical Operations Portfolio Leader
Product Development, Clinical Operations

Monica Eason
Clinical Operations Portfolio Leader
Product Development, Clinical Operation

Recruiting Positions	Number
Global Clinical Operations	2

2022-2024 FELLOWS

Caveen Datta, PharmD
University of North Carolina at Chapel Hill

Nick Olszewski, PharmD
University of Wisconsin - Madison

2023-2025 FELLOWS

Tyler Fukunaga, PharmD
University of Southern California

Liz Ilin, PharmD
St. John's University

Genentech
A Member of the Roche Group

CLINICAL SCIENCE
LATE STAGE DEVELOPMENT

OVERVIEW

The development of effective and safe medications for patients is our primary focus at Genentech. The mission of Product Development Clinical Science (PDC) is to develop and execute innovative and robust development programs to deliver well-characterized and differentiated medicines to patients with unmet medical need. PDC includes 3 therapeutic areas: Oncology/Hematology (PDOH), Neuroscience (PDN), and Immunology, Infectious Diseases, and Ophthalmology (I2O).

The Fellows accepted into our program will have a contributing role in clinical trial design and execution by assisting in writing protocols, informed consents, medical data review, scientific publications and presentations, as well as providing ongoing scientific guidance throughout study conduct. The Fellows may also be involved in the analysis of molecule-wide safety signals, analysis of study-related data, and contribute to authorship of regulatory documents.

ACTIVITIES

PDC specializes in late stage clinical development, conducting primarily Phase II/III clinical trials with an aim to further characterize the clinical efficacy and safety profile of a molecule before the registration/approval process. During the fellowship, the Fellow will receive professional experiences in the following capacities:

- Develop a deep understanding of the molecules in the late-stage pipeline
- Ascertain the risk/benefit profile of tested molecules and understand the criteria for moving further in development
- Author key scientific documentation for clinical studies
- Assist in ongoing clinical development plans by working closely with Clinical Scientists and Medical Directors on strategic initiatives
- Enhance scientific communication skills through presentations, medical congresses and professional meetings

PRECEPTORS

Sarah Troutman, PharmD
Senior Clinical Scientist,
Product Development
Oncology/Hematology

Iris To, PharmD
Senior Clinical Scientist,
Product Development
Oncology/Hematology

Jayla Briggs, PharmD,
Lead Clinical Scientist,
Product Development
Ophthalmology

Recruiting Positions	Number
Oncology/Hematology (PDOH)	1
Ophthalmology (PDI2O)	1

2022-2024 FELLOWS

Caroline Labib, PharmD
University of Washington

2023-2025 FELLOWS

Delaney McGuirt, PharmD
University of Maryland,
Baltimore

Taliah Qaiyim, PharmD
Florida Agricultural &
Mechanical University

Macy Gipson, PharmD
University of Southern
California

Trexy Palen, PharmD
University of Maryland,
Baltimore

Genentech
A Member of the Roche Group

PRODUCT DEVELOPMENT CLINICAL SAFETY

OVERVIEW

The Portfolio Clinical Safety (PCS) group within Product Development Safety delivers knowledge on the safety profiles of our medicines and defines how to manage risks to our patients. Our Pharm.D. fellow will work collaboratively with experienced PCS Safety Scientists and cross-functional colleagues to learn to monitor and manage the safety of our molecules. This includes exposure to molecules in both early development, late stage development and marketed medicines. The activities performed by PCS bring strategic, proactive, and scientific value to our pharmacovigilance and risk management strategies. This work ensures that Roche products maintain a positive benefit-risk balance for our patients.

ACTIVITIES

Fellow responsibilities include:

- Learning and understanding global requirements for the reporting and surveillance of adverse events
- Evaluation and analysis of adverse events received from clinical trials and from postmarketing reports
- Maintenance and update of safety related information in product labels, investigator brochures, and informed consent forms
- Contributing to safety strategy in study design and study management
- Preparation of aggregate safety reports for health authorities
- Risk management plan development and maintenance
- Cross-functional interactions with other departments within Product Development and the broader Roche organization
- Special projects

PRECEPTORS

Sam McCallum, PharmD
Safety Director
Late Stage and Marketed Medicine Safety

Sam Lim, PharmD
Associate Safety Director
Portfolio Clinical Safety

Recruiting Positions	Number
Clinical Safety	1

2022-2024 FELLOWS

Rutanshu Shah, PharmD
University of California, San Francisco

2023-2025 FELLOWS

Aleeza Sheikh, PharmD
University of Southern California

Genentech
A Member of the Roche Group

REGULATORY AFFAIRS

OVERVIEW

Regulatory professionals provide the interpretation of global regulations within their companies to facilitate drug development that meets the needs of Health Authorities, patients, and prescribers. Regulatory professionals are responsible for the design and implementation of regulatory strategies to optimally develop, license, and market products globally.

At Genentech, Regulatory Affairs Fellows will receive individual guidance from regulatory professionals and obtain an understanding of the regulatory roles and responsibilities in the drug development process.

Each Fellow will learn how to: apply regulations and health authority guidances in the drug development process, develop regulatory strategies in collaboration with global project teams, and interact with Health Authorities. In addition, the Regulatory Affairs Fellow may also have an opportunity to learn skills in medical writing, labeling, and regulatory submission publishing.

ACTIVITIES

The Fellow will acquire an understanding of the early and late stage drug development process across distinct therapeutic areas: Oncology, Immunology, Infectious Disease, Ophthalmology, and Neuroscience, through direct experience and/or exposure to:

- Regulatory Strategy
- Investigational New Drug Applications
- New Drug Applications
- Biologics License Applications
- Health Authority Interactions
- Labeling
- Post-Marketing Activities
- Clinical Regulatory Documentation
- Regulatory Intelligence
- Clinical Trial Conduct
- Companion Diagnostics
- Chemistry, Manufacturing, and Controls
- Regulatory Records and Information
- Submission Publishing and Management

During approximately the last 6 months of the second year of the Fellowship, Fellows will have the opportunity to participate in a broad range of rotations at Genentech or our holding company, Roche. Relocation will not be supported and fellows must have the relevant right to work, if seeking a rotation in a different geographic area outside the United States.

PRECEPTORS

Michael Stamatis, PharmD
Regulatory Senior Program Director
Product Development Regulatory

Jay Bordoloi, PharmD
Regulatory Senior Program Director
Product Development Regulatory

Sarah Bentouati, PharmD
Regulatory Program Management Leader
Product Development Regulatory

Recruiting Positions	Number
Regulatory Affairs	1

2022-2024 FELLOWS

Paulina Kepczynska, PharmD
University of Maryland, Baltimore

Shams Alqes, PharmD
University of California, San Diego

Nkechinyerem Ihenacho, PharmD
University of Illinois at Chicago

2023-2025 FELLOWS

Adesuwa Uwa-Omede, PharmD
Massachusetts College of Pharmacy and Health Sciences

Qianru Jing, PharmD
Northeastern University

Genentech
A Member of the Roche Group

US MEDICAL AFFAIRS / MEDICAL COMMUNICATIONS

OVERVIEW

The Medical Affairs / Medical Communications Fellowship is a two-year program designed to expose the Fellow to a broad range of US Medical Affairs activities, with a focus on Medical Communication activities.

During the first year, the fellow will learn how to effectively communicate customer-focused clinical information to patients, HCPs, and managed care entities through various channels, including digital channels. The fellow will also engage with external customers involved in evidence-based healthcare decisions such as managed care organizations, payors, PBMs, and clinical practice guidelines. Additionally, the fellow will support the development of innovative digital services and platforms to deliver exceptional customer experience.

The second year provides a unique opportunity to explore other departments through a few long-term rotations within Medical Affairs (eg, Medical team, Scientific Collaborations, Field Medical, Evidence Generation, US Patient Safety, Business Strategy & Operations). The focus of the second year is guided by the interests of the fellow and business opportunities.

ACTIVITIES

The primary goals of the Fellowship are to provide the Fellow with a thorough knowledge of Medical Affairs activities, and to build foundational scientific and professional skill sets required for a successful career within the pharmaceutical industry:

- Gain clinical proficiency and knowledge of key access strategies for a therapeutic area
- Monitor therapeutic landscapes and identify impactful opportunities for evidence exchange with key external access stakeholders to ensure accurate representation of Genentech products
- Evaluate medical literature and create accurate, fair-balanced medical content for external scientific engagement with customers within healthcare ecosystems
- Provide medical review of materials for both scientific exchange and promotional use
- Support pre-launch preparations for potential new molecular entities and label expansions
- Curate customer insights to identify strategic opportunities for medical teams
- Develop digital strategies to deliver exceptional customer experience
- Additional activities in second year based on rotations guided by the fellow's interests

PRECEPTORS

Linda Wang, PharmD
Principal Therapeutic Area Lead, US Medical Affairs

Neda Nguyen, PharmD
Senior Therapeutic Area Lead US Medical Affairs

Aileen Le, PharmD
Principal Therapeutic Area Lead, US Medical Affairs

Recruiting Positions	Number
USMA/Medical Communications	1

2022-2024 FELLOWS

Dalyna Quach, PharmD
University of Washington

2023-2025 FELLOWS

Aileen Nguyen Phan, PharmD
University of Maryland, Baltimore

So Young Kim, PharmD
University of California, San Francisco

Genentech
A Member of the Roche Group

US MEDICAL AFFAIRS / MEDICAL SCIENCE LIAISONS

OVERVIEW

A network of clinical and scientific collaborators is responsible for developing and executing medical strategy for both marketed and pipeline molecules for the US affiliate. The network supports Medical Science Liaison (MSL) activities by serving as subject matter experts and ensuring strategic alignment across Medical Affairs.

The US Medical Affairs / MSL Fellowship is a two-year program based in South San Francisco, designed to expose the Fellow to a broad range of corporate and field-based US Medical Affairs activities within their assigned Medical Unit. The focus of the second year is determined by the mutual interests of the Fellow and the company.

ACTIVITIES

Medical Affairs Component:

The Fellowship will provide the Fellow with a thorough knowledge of US Medical Affairs core functions and develop foundational scientific and professional skill sets required for a successful career. The Fellow will have the opportunity to participate in or lead:

- Tactic execution with the Medical Directors and Medical Science Directors who support medical strategy
- Pre- and peri-approval preparations for new molecular entities
- Clinical insights with colleagues across various cross-functional departments
- Development of training and tools for the Field Medical Team
- Collaborative studies and activities across NCI, Academic Alliances, and Community Networks

MSL Component:

Alongside the Medical Affairs experience, the Fellow will have the opportunity to participate in or lead:

- MSL strategy planning and execution with MSL leadership
- In-field scientific exchange with providers and key opinion leaders
- Execution of advisory boards and congress tactics

PRECEPTORS

Jessica Priest, PharmD
Principal Medical Science Liaison
Neuroimmunology

Todd Okamoto, PharmD
MSL Field Director (West)
Lung/GU/Derm Oncology

Jan Bhagwakar, PharmD
MSL Field Director (SE/Central)
Lung/GU/Derm Oncology



Ilze Bara, MD, MBA, LA
Executive Director,
Medical Partner

Nikki Win, PhD
Principal Medical Science Director,
OMNI Scientific Strategy &
Collaborations

Recruiting Positions	Number
USMA/MSL Solid Tumors	1
USMA/MSL Neuroscience	1

2022-2024 FELLOWS

Chris Cousin, PharmD
Massachusetts College of Pharmacy and Health Sciences

Isabelle Tharp, PharmD
Drake University

2023-2025 FELLOWS

Reilly Fortney, PharmD
University of California, San Francisco

Grace Brent, PharmD
Drake University

Genentech
A Member of the Roche Group

USMA / CLINICAL OPERATIONS / STUDY LEADERSHIP

Not recruiting for 2024

OVERVIEW

At Roche/Genentech, we have a bold Pharma Vision to achieve 3-5 times more patient benefit at 50% less cost to society. With this vision top of mind, US Medical Affairs (USMA) envisions to deliver tomorrow's medical advances faster to more patients by improving care experience, cost and health of society. We seek to deliver our vision by developing studies with novel designs to improve quality, speed, cost, and customer experience, while leading next-generation studies in underserved populations.

Leading cross-functionally, fellows will contribute to the delivery of the USMA portfolio of clinical studies and programs across Disease Areas by providing strategic input and operational leadership/guidance.

Within USMA Evidence Generation, Genentech hosts a fellowship in Study Leadership.

ACTIVITIES

Fellow responsibilities may include:

- Providing direction and leadership to one or more study teams to ensure delivery of all cross functional activities to meet study plans outlined in medical plans
- Contribute clinical operations expertise into medical plans and study design, timelines and budget
- Chair study team meetings and other meetings involving external partners/stakeholders (investigators, vendors, as appropriate), and compliantly develop and cultivate productive relationships
- Build and maintain effective high performing study teams by ensuring clarity of roles, responsibilities, accountabilities, and deliverables for team members
- Provide Contract Research Organization (CRO) and other vendor(s) direction and oversight, and ensure they deliver against contracted scope of work

PRECEPTORS

Jenny Chang, PharmD, MBA
Clinical Program Leader
US Medical Affairs,
Evidence Generation

Angeline Lo, PharmD, MA
Senior Clinical Trial Leader
US Medical Affairs,
Evidence Generation

Salah El-Saheb, PharmD
Executive Director, Evidence Generation Leader – OMNI Portfolio, US Medical Affairs, Evidence Generation

2023-2025 FELLOWS

Amir Chadha, PharmD
University of the Pacific

Genentech
A Member of the Roche Group

PHARMA PARTNERING

Not recruiting for 2024

OVERVIEW

Partnering strengthens Roche's internal research, development, and commercial portfolio by building alliances with world-class leaders in the pharmaceutical and biotechnology industries. By mobilizing other functions at Roche and Genentech, Partnering maximizes the potential of these assets through creative deal terms and fostering a collaborative relationship with the external partner. In Pharma Partnering, the Fellow has the opportunity to work in the Business Development and Alliance Management Groups.

ACTIVITIES

The Business Development role encompasses "Want," "Find," and "Get," including:

WANT and FIND

- Scouting: Identify new partnering opportunities using internal and external sources. Prepare in-depth competitive landscape analyses, reviews of disease biology and unmet need in areas of interest. Support preparation and analysis of scientific, partnering, and investor conferences.
- Triage: Support initial screening and review of data packages from Biotech and Pharma partners to determine Roche interest based on: mechanism of action, link to human disease biology, unmet need, strategic fit, and commercial opportunity.

GET

- Due Diligence: Work in close collaboration with BD Project Leader (BDPL) to assist in data review, DD team debriefs, and preparation of proposals to senior management.
- Deal Team: For deal negotiations, work with BDPL to prepare term sheets, governance, and contracting.

The Global Alliance and Asset Management role encompasses "Manage", including:

- Liaising with the alliance counterpart and senior leadership of partner companies.
- Effective leadership of collaborations between external companies and Genentech/Roche.
- Integral part of the Business Development deal team during deal negotiations and contracting.
- Lead and negotiate deals arising from existing alliances.
- Establish and lead joint governance committee meetings to ensure appropriate decision making on partnered programs.
- Participate in out-partnering or divestment opportunities.

PRECEPTORS

Beth Odeh-Frikert, PharmD
Head SSF Global Alliance and Asset Management,
Pharma Partnering

Patrick Schleck, PharmD, MBA
Vice President,
Head of Oncology Partnering Pharma Partnering

2023-2025 FELLOWS

Jemal Hussein, PharmD
Keck Graduate Institute

~50% of **R&D pipeline** involves a partnership

220+ partnerships managed and **93** new agreements signed in 2020 by Pharma Partnering

1 *Want* Defining our search

2 *Find* Identifying Partners

3 *Get* Personalizing deals

4 *Manage* Building relationships

Genentech
A Member of the Roche Group

RUTGERS
Ernest Mario School of Pharmacy

Soaring Ever Higher
Pharmaceutical Industry Fellowship Program

Rutgers Pharmaceutical Industry Fellowship Program

Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey

Program History

In 1984, at Rutgers, The State University of New Jersey, the Ernest Mario School of Pharmacy and two pharmaceutical companies began a first-of-its-kind collaborative pilot program to evaluate the potential contributions of clinically-trained pharmacists within a pharmaceutical industry practice setting. Following the successful pilot, the Rutgers Pharmaceutical Industry Fellowship (RPIF) Program grew significantly and expanded to include 27 companies within the pharmaceutical and biopharmaceutical industry and approximately 350 Fellows.

In 2002, Dr. Ernest Mario generously provided an endowment to establish the ***Institute for Pharmaceutical Industry Fellowships*** to enhance and promote the role of pharmacists in industry through the RPIF Program. The Institute staff members:

- provide leadership and administrative support
- promote quality, communication, scholarly activity, and professional development
- arrange specialized Fellowship training opportunities within the pharmaceutical and biopharmaceutical industry.

In 2018, our Program expanded to offer interdisciplinary Fellows' training by adding select physician Fellowship opportunities to our well-established program.

The RPIF Program has thrived under the leadership of the founder, Dr. Joseph A. Barone, Dean and Professor II of the Ernest Mario School of Pharmacy, Dr. Carolyn Seyss, the Director for the Institute for Pharmaceutical Industry Fellowships, and Dr. Michael Toscani as the Director Emeritus.

The RPIF Program Certificate is now associated with special credentials so our alumni can now proudly identify themselves as **RUCIF (Rutgers University Certified Industry Fellow)**. Well over 1,500 Post-Doctoral Fellows have completed the RPIF Program, most of whom are experiencing influential and rewarding careers in the pharmaceutical and biopharmaceutical industry throughout the US and abroad. The RPIF Program has Preceptors and Mentors from industry who share their knowledge and experiences with the Fellows through an intense but closely-guided training program. Assignments and projects are challenging, meaningful, and designed to enhance understanding of the pharmaceutical and biopharmaceutical industry and the Fellow's functional area(s). Our goal is to provide the environment for Fellows to build the foundations to fuel their careers as future leaders in the industry.

Connect with us on social media: @RutgersFellow

Joseph A. Barone, Pharm.D., F.C.C.P.
Dean and Professor II
Ernest Mario School of Pharmacy
Rutgers University

Carolyn Seyss, Pharm.D., RUCIF
Fellowship Director
Institute for Pharmaceutical Industry Fellowships
Ernest Mario School of Pharmacy

Michael Toscani, Pharm.D.
Research Professor,
Fellowship Director Emeritus
Institute for Pharmaceutical Industry Fellowships

RUTGERS
Institute for Pharmaceutical Industry Fellowships

RUTGERS
Ernest Mario School of Pharmacy

Soaring Ever Higher

Pharmaceutical Industry Fellowship Program

Key Program Features

The Rutgers Pharmaceutical Industry Fellowship Program **FOSTER**s the growth and development of future pharmaceutical and biopharmaceutical industry professionals and leaders through key program features:

F	**Family of Leading Companies** – Partners include several of the top global pharmaceutical and biopharmaceutical companies and offer large to small company environments.
O	**Outstanding Alumni Track Record** – Well over 1,500 alumni hold prominent positions at many leading companies, including VP and C-suite levels.
S	**Strong Network** — Fellows develop valuable, lasting connections with each other, alumni, Preceptors, and Rutgers EMSOP faculty.
T	**Trusted and Proven Since 1984** — the Rutgers Fellowship Program is nationally recognized, trusted, and proven as the key pathway to industry for pharmacists as future leaders.
E	**Enhanced Career Development** – Breadth of experiences informs career path choices, increasingly challenging assignments build depth of experience, and visibility creates opportunities - enhancing the potential for accelerated career paths.
R	**Rigorous Academic Component** – Rutgers affiliation provides academic and professional development opportunities.

Rutgers, The State University of New Jersey, with over 67,000 students in its three campuses, is one of the major state university systems in the United States. The New Jersey College of Pharmacy was founded in 1892 and was incorporated into the University in 1927. The Ernest Mario School of Pharmacy (EMSOP) is part of Rutgers Biomedical and Health Sciences (RBHS), the only state school of pharmacy in New Jersey, with approximately 1,350 students in its Doctor of Pharmacy degree program. The Rutgers EMSOP is located on the University's main science and technology campus in Piscataway, New Jersey. Because of its relationship with and close proximity to most of the nation's leading pharmaceutical and biopharmaceutical companies, the EMSOP and the RPIF Program are uniquely capable of providing Fellows with advanced training in the pharmaceutical and biopharmaceutical industry.

Connect with us on social media: @RutgersFellow

Professional Development Series

All Fellows gather once monthly as a group to participate in the Professional Development Day (PDD) series, an important component of their training that complements the hands-on experience provided at the partner companies. The PDDs are steered by a committee of Fellows and are designed to enhance the Fellows' leadership skills such as emotional intelligence, communication, critical decision making, and presentation skills. Fellows develop skill sets under the guidance of external trainers and accomplished RPIF alumni. PDDs also provide general knowledge about various aspects of drug development/commercialization and issues facing the pharmaceutical and biopharmaceutical industry, and promote connectivity and a sense of community among Fellows and alumni from different companies and disciplines.

The Fellows can learn from each other through individual and group presentations on topics and issues related to the pharmaceutical and biopharmaceutical industry. The dynamic forum of PDD provides an opportunity for open discussion and debate among Fellows, Rutgers faculty, and company Preceptors. In addition, outside experts provide training and professional development in a variety of areas (e.g., tools for corporate success, professional writing, presentations, meeting facilitation, negotiating, influencing, networking, conflict resolution, giving and receiving feedback, and business etiquette). Other PDD guest speakers include senior industry executives, including our successful RPIF Program alumni, who share their career paths, insights, and experiences. Importantly, PDDs provide an excellent opportunity for Fellows to interact with each other and develop lasting personal friendships and a strong professional network of Fellows, faculty, alumni, and other industry executives.

RUTGERS
Institute for Pharmaceutical Industry Fellowships

RUTGERS
Ernest Mario School of Pharmacy

Soaring Ever Higher
Pharmaceutical Industry Fellowship Program

Application Process and Eligibility Requirements:
Pharmacy Fellows for the Rutgers Pharmaceutical Industry Fellowship Program are selected on a nationally competitive basis. Candidates must have completed a Doctor of Pharmacy degree from an ACPE-accredited institution before July 1 of the fellowship term.

How to Apply:
The RPIF Program is highly competitive. Candidates will be selected for interviews on a rolling basis, so we strongly encourage you to submit your application as soon as possible.

Interested candidates may submit their application with short-answer questions and supporting materials (letter of intent, curriculum vitae, and 3 letters of recommendation) as soon as October 6, 2023 by visiting our website at: https://pharmafellows.rutgers.edu/how-to-apply/

All application materials **must be submitted electronically to the RPIF Website** per instructions on the site.

Required Items	Submit by
Application with short-answer questions	**October 13th**
Letter of Intent (LOI)	**October 13th**
Curriculum Vitae (CV)	**October 13th**
Letters of Recommendation (LORs)	**December 1st**

Your Letter of Intent & Letters of Recommendation should be addressed to:

Joseph A. Barone, Pharm.D., F.C.C.P.
Dean and Professor II
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
160 Frelinghuysen Road
Piscataway, NJ 08854-8020

Alliance of Industry Fellowship Associates Fellowship Offers
Recognizing that the choice of a Post-Doctoral Industry Fellowship is an important decision, AIFA exists to promote a common aspect of each of our program's cultures by supporting a consensus first offer date of December 13, 2023 for all fellowship candidates.

We hope that other academic and non-academic Fellowship Programs will respect this timeline to allow for best program fit for candidates.

AIFA
Alliance of Industry Fellowship Associates

Connect with us on social media: @RutgersFellow

RUTGERS
Institute for Pharmaceutical Industry Fellowships